Exchange: NASDAQ·Updated 04:26 PM EDT
AMPH logo

AMPHAmphastar Pharmaceuticals Inc

$19.02
$0.14
(0.74%)
Today
Closed $19.02
$0.00
(0.00%)
After Hours
EarningsAug 6
Mkt Cap$832.47M
Vol446,629.00
News
all
press releases
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
Zacks
News Placeholder
More News
News Placeholder
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
Zacks
News Placeholder
New Strong Sell Stocks for June 23rd
ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.
Zacks
News Placeholder
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty...
Yahoo! Finance: News
News Placeholder
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
News Placeholder
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of -40.28% and +0.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +110.71% and +10.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) have been given a consensus rating of "Hold" by the nine ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and tw...
MarketBeat
News Placeholder
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
AMPH vs. RDY: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
<
1
2
...
>

Advertisement|Remove ads.